Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVIGATE: Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
NCT04365868Phase 3Terminated
- Sponsor
- Galectin Therapeutics
- Start
- Jun 2020
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of belapectin in Nonalcoholic steatohepatitis (NASH) and Cirrhosis (3 arms), sponsored by Galectin Therapeutics. Primary endpoint: Proportion of Patients Who Develop New Esophageal Varices at 78 weeks. Started Jun 2020; status: terminated.
02
Drugs
belapectin
03
Conditions
Nonalcoholic steatohepatitis (NASH)Cirrhosis
Beyond the preview
Go deeper on NCT04365868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365868.